دورية أكاديمية
أعرض في EDS

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

التفاصيل البيبلوغرافية
العنوان: Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
المؤلفون: Tentori CA; Humanitas Clinical and Research Center-IRCCS & Department of Biomedical Sciences Humanitas University Milan Italy.; Comprehensive Cancer Centre, King's College London UK., Zhao LP; Hématologie seniors Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP) Paris France.; INSERM UMR_S1160, Institut de Recherche Saint Louis Université Paris Cité Paris France., Tinterri B; Humanitas Clinical and Research Center-IRCCS & Department of Biomedical Sciences Humanitas University Milan Italy., Strange KE; Comprehensive Cancer Centre, King's College London UK.; Research Group of Molecular Immunology Francis Crick Institute London UK., Zoldan K; Department of Medicine 1, Haematology, Cellular Therapy, Hemostaseology and Infectious Diseases University Medical Center Leipzig Leipzig Germany., Dimopoulos K; Department of Clinical Biochemistry Bispebjerg and Frederiksberg Hospital Copenhagen Denmark.; Department of Pathology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark., Feng X; Hematology Branch, National Heart, Lung and Blood Institute Bethesda Maryland USA., Riva E; Humanitas Clinical and Research Center-IRCCS & Department of Biomedical Sciences Humanitas University Milan Italy., Lim B; Imperial College London London UK., Simoni Y; Université Paris Cité, CNRS, INSERM, Institut Cochin Paris France., Murthy V; Centre for Clinical Haematology, University Hospitals of Birmingham Birmingham UK., Hayes MJ; Cell & Developmental Biology Vanderbilt University School of Medicine Nashville Tennessee USA.; Pathology, Microbiology and Immunology, Vanderbilt University Medical Center Nashville Tennessee USA.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center Nashville Tennessee USA., Poloni A; Department of Clinical and Molecular Sciences Università Politecnica delle Marche Ancona Italy., Padron E; Moffitt Cancer Center, Malignant Hematology Department Tampa USA., Cardoso BA; Universidade Católica Portuguesa Faculdade de Medicina Portugal.; Universidade Católica Portuguesa, Centro de Investigação Interdisciplinar em Saúde Portugal., Cross M; Department of Medicine 1, Haematology, Cellular Therapy, Hemostaseology and Infectious Diseases University Medical Center Leipzig Leipzig Germany., Winter S; Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden Dresden Germany., Santaolalla A; Comprehensive Cancer Centre, King's College London UK., Patel BA; Hematology Branch, National Heart, Lung and Blood Institute Bethesda Maryland USA., Groarke EM; Hematology Branch, National Heart, Lung and Blood Institute Bethesda Maryland USA., Wiseman DH; Division of Cancer Sciences The University of Manchester Manchester UK.; The Christie NHS Foundation Trust Manchester UK., Jones K; Immunophenotyping Laboratory (Synnovis Analytics LLP) Southeast Haematological Malignancy Diagnostic Service, King's College Hospital London UK., Jamieson L; Immunophenotyping Laboratory (Synnovis Analytics LLP) Southeast Haematological Malignancy Diagnostic Service, King's College Hospital London UK., Manogaran C; Immunophenotyping Laboratory (Synnovis Analytics LLP) Southeast Haematological Malignancy Diagnostic Service, King's College Hospital London UK., Daver N; University of Texas MD Anderson Cancer Center Houston, Texas USA., Gallur L; Hematology Department, Vall d'hebron University Hospital, Vall d'hebron Institut of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain., Ingram W; Department of Haematology University Hospital of Wales Cardiff UK., Ferrell PB; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center Nashville Tennessee USA.; Vanderbilt University Medical Center Nashville Tennessee USA., Sockel K; Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden Dresden Germany., Dulphy N; INSERM UMR_S1160, Institut de Recherche Saint Louis Université Paris Cité Paris France.; Laboratoire d'Immunologie et d'Histocompatibilité, Assistance Publique des Hôpitaux de Paris (APHP), Hôpital Saint-Louis Paris France.; Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis Paris France., Chapuis N; Université Paris Cité, CNRS, INSERM, Institut Cochin Paris France.; Assistance Publique-Hôpitaux de Paris Centre, Hôpital Cochin Paris France., Kubasch AS; Department of Medicine 1, Haematology, Cellular Therapy, Hemostaseology and Infectious Diseases University Medical Center Leipzig Leipzig Germany., Olsnes AM; Section for Hematology, Department of Medicine Haukeland University Hospital Bergen Norway.; Department of Clinical Science Faculty of Medicine, University of Bergen Bergen Norway., Kulasekararaj A; Department of Haematology King's College Hospital, Denmark Hill London UK., De Lavellade H; Haematology Department Guy's and St Thomas NHS Trust London UK., Kern W; MLL Münchner Leukämielabor Munich Germany., Van Hemelrijck M; Comprehensive Cancer Centre, King's College London UK., Bonnet D; Hematopoietic Stem Cell Laboratory Francis Crick Institute London UK., Westers TM; Department of Hematology, Cancer Center Amsterdam Amsterdam University Medical Centers, location VU University Medical Center Amsterdam The Netherlands., Freeman S; Institute of Immunology and Immunotherapy University of Birmingham Birmingham UK., Oelschlaegel U; Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden Dresden Germany., Valcarcel D; Hematology Department, Vall d'hebron University Hospital, Vall d'hebron Institut of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain., Raddi MG; Myelodysplastic Syndrome Unit, Hematology Division Azienda Ospedaliero-Universitaria Careggi, University of Florence Florence Italy., Grønbæk K; Department of Hematology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark.; Biotech Research and Innovation Center (BRIC) University of Copenhagen Copenhagen Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark., Fontenay M; Université Paris Cité, CNRS, INSERM, Institut Cochin Paris France.; Assistance Publique-Hôpitaux de Paris Centre, Hôpital Cochin Paris France., Loghavi S; University of Texas MD Anderson Cancer Center Houston, Texas USA., Santini V; Myelodysplastic Syndrome Unit, Hematology Division Azienda Ospedaliero-Universitaria Careggi, University of Florence Florence Italy., Almeida AM; Hematology Department Hospital da Luz Lisboa Lisboa Portugal.; Deanery Faculdade de Medicina, UCP Lisboa Portugal., Irish JM; Cell & Developmental Biology Vanderbilt University School of Medicine Nashville Tennessee USA.; Pathology, Microbiology and Immunology, Vanderbilt University Medical Center Nashville Tennessee USA.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center Nashville Tennessee USA., Sallman DA; Moffitt Cancer Center, Malignant Hematology Department Tampa USA., Young NS; Hematology Branch, National Heart, Lung and Blood Institute Bethesda Maryland USA., van de Loosdrecht AA; Department of Hematology, Cancer Center Amsterdam Amsterdam University Medical Centers, location VU University Medical Center Amsterdam The Netherlands., Adès L; Hématologie seniors Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP) Paris France.; Université Paris Cité, CNRS, INSERM, Institut Cochin Paris France., Della Porta MG; Humanitas Clinical and Research Center-IRCCS & Department of Biomedical Sciences Humanitas University Milan Italy., Cargo C; Leeds Teaching Hospital Leeds UK., Platzbecker U; Department of Medicine 1, Haematology, Cellular Therapy, Hemostaseology and Infectious Diseases University Medical Center Leipzig Leipzig Germany., Kordasti S; Comprehensive Cancer Centre, King's College London UK.; Department of Clinical and Molecular Sciences Università Politecnica delle Marche Ancona Italy.; Haematology Department Guy's and St Thomas NHS Trust London UK.
مؤلفون مشاركون: i4MDS consortium
المصدر: HemaSphere [Hemasphere] 2024 May 15; Vol. 8 (5), pp. e64. Date of Electronic Publication: 2024 May 15 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2024- : [Hoboken, NJ] : Wiley
Original Publication: [Philadelphia, PA] : Wolters Kluwer Health, Inc., [2017]-
مستخلص: Advancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly in recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While molecular inclusions into prognostic models have substantively advanced risk stratification, recent revelations have emphasized the pivotal role of immune dysregulation within the bone marrow milieu during MDS evolution. Nonetheless, immunotherapy for MDS has not experienced breakthroughs seen in other malignancies, partly attributable to the absence of an immune classification that could stratify patients toward optimally targeted immunotherapeutic approaches. A pivotal obstacle to establishing "immune classes" among MDS patients is the absence of validated accepted immune panels suitable for routine application in clinical laboratories. In response, we formed International Integrative Innovative Immunology for MDS (i4MDS), a consortium of multidisciplinary experts, and created the following recommendations for standardized methodologies to monitor immune responses in MDS. A central goal of i4MDS is the development of an immune score that could be incorporated into current clinical risk stratification models. This position paper first consolidates current knowledge on MDS immunology. Subsequently, in collaboration with clinical and laboratory specialists, we introduce flow cytometry panels and cytokine assays, meticulously devised for clinical laboratories, aiming to monitor the immune status of MDS patients, evaluating both immune fitness and identifying potential immune "risk factors." By amalgamating this immunological characterization data and molecular data, we aim to enhance patient stratification, identify predictive markers for treatment responsiveness, and accelerate the development of systems immunology tools and innovative immunotherapies.
Competing Interests: Shahram Kordasti: Novartis: Advisory Board, Speakers bureau, Alexion: Speakers bureau, Beckman Coulter: Speakers bureau, MorphoSys: Research Support (none is related to this publication). Wolfgang Kern declares part‐ownership of MLL Munich Leukemia Laboratory. Austin Kulasekararaj: Research support (to institution): Celgene/BMS and Novartis. Speaker's fees: Alexion/AstraZeneca, Akari, Apellis, Celgene/BMS, Novartis, Pfizer, Ra Pharma/UCB, Roche, SOBI. Scientific advisory board: Alexion/Astra Zeneca, Apellis, Amgen, Agios, Biocryst, Celgene/BMS, Novartis, Pfizer, Regeneron, Roche, SOBI, Janssen, Samsung and Novo Nordisk (none is related to this publication).
(© 2024 The Authors. HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematology Association.)
References: Blood Adv. 2021 Nov 23;5(22):4535-4548. (PMID: 34614508)
Leukemia. 2019 Aug;33(8):2034-2046. (PMID: 30737486)
Leuk Res. 2008 Sep;32(9):1407-16. (PMID: 18405968)
Haematologica. 2015 Jun;100(6):e220-2. (PMID: 25749828)
Front Immunol. 2021 Apr 27;12:665541. (PMID: 33986753)
Blood. 2011 Oct 6;118(14):3765-76. (PMID: 21753188)
Leukemia. 2007 Dec;21(12):2411-9. (PMID: 17805323)
Front Oncol. 2020 Aug 07;10:1595. (PMID: 32903786)
J Clin Oncol. 2010 Dec 10;28(35):5166-73. (PMID: 21041705)
J Immunol. 2012 Sep 15;189(6):3198-208. (PMID: 22875800)
Eur J Haematol. 2009 Mar;82(3):201-7. (PMID: 19018862)
Blood. 2007 Aug 1;110(3):847-50. (PMID: 17412885)
Haematologica. 2011 Apr;96(4):602-6. (PMID: 21160069)
Leukemia. 2010 Sep;24(9):1607-16. (PMID: 20613786)
Blood Cells Mol Dis. 2021 Feb;86:102507. (PMID: 33032166)
Br J Haematol. 2004 Sep;126(6):806-14. (PMID: 15352984)
Leukemia. 2020 Sep;34(9):2460-2472. (PMID: 32099035)
Exp Hematol. 2001 Nov;29(11):1270-7. (PMID: 11698122)
Oncoimmunology. 2015 Jun 24;5(2):e1062208. (PMID: 27057428)
Hematol Oncol Stem Cell Ther. 2013 Jun;6(2):49-57. (PMID: 23714180)
Stem Cells Dev. 2014 Jul 15;23(14):1568-81. (PMID: 24617415)
Int J Hematol. 2002 Apr;75(3):289-97. (PMID: 11999358)
Leukemia. 2021 Sep;35(9):2720-2724. (PMID: 33623140)
Haematologica. 2008 Mar;93(3):381-9. (PMID: 18268282)
Exp Hematol. 2009 Aug;37(8):947-55. (PMID: 19409953)
Clin Immunol. 2011 Jun;139(3):350-9. (PMID: 21444247)
Leukemia. 2022 Jul;36(7):1703-1719. (PMID: 35732831)
Ann Hematol. 2018 Aug;97(8):1349-1356. (PMID: 29572561)
Blood. 2002 Nov 15;100(10):3639-45. (PMID: 12393644)
J Clin Oncol. 2020 May 20;38(15):1723-1735. (PMID: 32058844)
Am J Hematol. 2000 Aug;64(4):271-4. (PMID: 10911379)
Br J Haematol. 1999 Dec;107(4):844-50. (PMID: 10606893)
J Clin Oncol. 2011 Jan 20;29(3):303-9. (PMID: 21149672)
Br J Haematol. 2019 Apr;185(2):357-360. (PMID: 30010189)
Exp Cell Res. 2021 Nov 1;408(1):112837. (PMID: 34547255)
Haematologica. 2015 May;100(5):643-52. (PMID: 25682594)
Leuk Res. 2012 Mar;36(3):287-92. (PMID: 22133642)
Leuk Lymphoma. 2019 Oct;60(10):2457-2463. (PMID: 30947589)
Leuk Res. 2016 Dec;51:49-55. (PMID: 27846431)
Leukemia. 2006 Mar;20(3):463-70. (PMID: 16408099)
Blood. 2003 Sep 1;102(5):1866-8. (PMID: 12730116)
Int J Hematol. 2021 May;113(5):723-734. (PMID: 33502734)
Leukemia. 2022 Nov;36(11):2739-2742. (PMID: 36104395)
Cancer Immunol Immunother. 2019 Dec;68(12):2015-2027. (PMID: 31705171)
Exp Hematol. 2010 Aug;38(8):677-84. (PMID: 20394797)
Leukemia. 2012 Apr;26(4):693-9. (PMID: 21912394)
Stem Cells Dev. 2010 Jul;19(7):1043-54. (PMID: 19788374)
Cytometry B Clin Cytom. 2023 Jan;104(1):15-26. (PMID: 34894176)
Cell Rep. 2022 May 10;39(6):110805. (PMID: 35545056)
Am J Transl Res. 2017 Jul 15;9(7):3462-3468. (PMID: 28804562)
Blood. 2016 Dec 15;128(24):2819-2823. (PMID: 27760759)
Blood. 2016 Feb 4;127(5):616-25. (PMID: 26637787)
Stem Cells Dev. 2012 Jul 1;21(10):1604-15. (PMID: 21933023)
Haematologica. 2009 Apr;94(4):496-506. (PMID: 19229054)
Leuk Res. 2001 Dec;25(12):1075-83. (PMID: 11684279)
Blood Cancer J. 2019 Aug 9;9(8):63. (PMID: 31399557)
Nat Commun. 2023 Feb 3;14(1):588. (PMID: 36737440)
PLoS One. 2012;7(9):e45675. (PMID: 23029178)
Leukemia. 2009 Mar;23(3):510-8. (PMID: 19020538)
Leukemia. 2014 Jun;28(6):1280-8. (PMID: 24270737)
Front Oncol. 2021 Jan 11;10:585216. (PMID: 33505909)
Hemasphere. 2019 Jan 28;3(1):e168. (PMID: 31723807)
Asian Pac J Cancer Prev. 2020 Oct 01;21(10):2949-2953. (PMID: 33112553)
Oncol Lett. 2018 Apr;15(4):5497-5504. (PMID: 29556297)
J Leukoc Biol. 2018 Sep;104(3):641-647. (PMID: 29656609)
J Exp Med. 2022 Mar 7;219(3):. (PMID: 35089323)
PLoS One. 2012;7(12):e51339. (PMID: 23236476)
Front Immunol. 2015 Jul 27;6:380. (PMID: 26284066)
Leukemia. 1997 Dec;11(12):2049-54. (PMID: 9447819)
Blood. 2010 Nov 18;116(20):4251-61. (PMID: 20679526)
Analyst. 2019 May 13;144(10):3250-3259. (PMID: 31049499)
Leukemia. 2022 Jul;36(7):1947-1950. (PMID: 35597805)
Front Oncol. 2017 Aug 08;7:164. (PMID: 28848706)
Haematologica. 2013 Nov;98(11):1677-85. (PMID: 23716561)
Blood. 2012 Sep 20;120(12):2454-65. (PMID: 22740453)
Leuk Res. 2007 Oct;31(10):1373-82. (PMID: 17188353)
Leukemia. 2023 Aug;37(8):1709-1718. (PMID: 37420006)
Blood. 2005 Nov 1;106(9):2982-91. (PMID: 16076868)
Cytometry B Clin Cytom. 2016 Jul;90(4):337-48. (PMID: 26502918)
DNA Cell Biol. 2015 Sep;34(9):588-95. (PMID: 26154600)
Cell Immunol. 2016 Oct;308:19-26. (PMID: 27417453)
Haematologica. 2022 Mar 01;107(3):655-667. (PMID: 33567812)
Blood. 2007 Jun 1;109(11):4816-24. (PMID: 17341666)
Int J Lab Hematol. 2008 Oct;30(5):390-9. (PMID: 19046314)
Blood. 2021 Nov 4;138(18):1727-1732. (PMID: 34139005)
Cell Stem Cell. 2023 Jun 1;30(6):781-799.e9. (PMID: 37267914)
Cancer Immunol Immunother. 2016 Sep;65(9):1135-47. (PMID: 27481108)
Nat Rev Cancer. 2013 Oct;13(10):739-52. (PMID: 24060865)
J Immunol Res. 2016;2016:9404705. (PMID: 27722177)
Eur J Haematol. 2022 Oct;109(4):398-405. (PMID: 35775392)
Leukemia. 2019 Jun;33(6):1487-1500. (PMID: 30575819)
J Clin Invest. 2013 Nov;123(11):4595-611. (PMID: 24216507)
J Immunol Res. 2016;2016:5479013. (PMID: 28074192)
Leukemia. 2013 Sep;27(9):1841-51. (PMID: 23797473)
Haematologica. 2020 Apr;105(4):961-971. (PMID: 31273091)
Stem Cell Res Ther. 2018 Oct 25;9(1):271. (PMID: 30359303)
Cell Prolif. 2020 May;53(5):e12819. (PMID: 32372504)
Br J Haematol. 2010 Jan;148(1):90-8. (PMID: 19793254)
Int J Lab Hematol. 2009 Dec;31(6):630-8. (PMID: 18691343)
Leuk Lymphoma. 1994 May;13(5-6):471-7. (PMID: 8069192)
Leuk Res. 2007 Nov;31(11):1469-78. (PMID: 17360037)
Haematologica. 1995 May-Jun;80(3):212-8. (PMID: 7672714)
Cancer Lett. 2012 Apr 28;317(2):136-43. (PMID: 22240014)
DNA Cell Biol. 2012 Oct;31(10):1563-70. (PMID: 22873198)
Vet Immunol Immunopathol. 2016 Dec;182:69-73. (PMID: 27863553)
Leukemia. 2007 Apr;21(4):659-67. (PMID: 17301813)
Oncoimmunology. 2013 Feb 1;2(2):e23138. (PMID: 23525654)
Innate Immun. 2020 Nov;26(8):703-715. (PMID: 33050756)
Clin Exp Med. 2023 Jul;23(3):787-801. (PMID: 35916958)
Leuk Res. 2002 Jul;26(7):677-86. (PMID: 12008086)
Exp Hematol. 2016 Jan;44(1):75-83.e1-4. (PMID: 26521017)
Int J Hematol. 2001 Jun;73(4):483-491. (PMID: 11503963)
Blood. 2023 Apr 6;141(14):1768-1772. (PMID: 36720101)
Leuk Res. 2012 Mar;36(3):331-3. (PMID: 22177732)
Haematologica. 2015 Feb;100(2):194-204. (PMID: 25361944)
Blood. 2015 Jun 4;125(23):3618-26. (PMID: 25852055)
Blood. 2011 Aug 4;118(5):e16-31. (PMID: 21653326)
Clin Immunol. 2004 Dec;113(3):310-7. (PMID: 15507396)
Cytometry B Clin Cytom. 2016 Jul;90(4):349-57. (PMID: 26648320)
Blood. 2014 May 8;123(19):3016-26. (PMID: 24652987)
PLoS One. 2013 Aug 19;8(8):e72138. (PMID: 23977231)
Br J Haematol. 2000 Dec;111(3):863-72. (PMID: 11122148)
J Clin Oncol. 2023 May 20;41(15):2827-2842. (PMID: 36930857)
Leuk Res. 2008 Jul;32(7):1026-35. (PMID: 18006057)
Eur J Haematol. 2013 May;90(5):375-84. (PMID: 23331180)
NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. (PMID: 38319256)
Leuk Res. 2013 Mar;37(3):266-73. (PMID: 23153526)
Br J Haematol. 2009 Apr;145(1):64-72. (PMID: 19210506)
Blood. 2017 Mar 30;129(13):1881-1883. (PMID: 28159734)
Blood. 2016 Dec 22;128(25):2960-2975. (PMID: 27737891)
Eur J Haematol. 2014 Dec;93(6):476-86. (PMID: 24889123)
Tumour Biol. 2014 May;35(5):4307-16. (PMID: 24443267)
Oncoimmunology. 2016 May 13;5(10):e1183860. (PMID: 27853634)
Blood. 2023 Jul 20;142(3):244-259. (PMID: 37084382)
Blood. 2018 Jul 19;132(3):277-280. (PMID: 29764839)
Rheumatology (Oxford). 2016 Feb;55(2):291-300. (PMID: 26350487)
Acta Haematol. 2012;128(3):178-82. (PMID: 22890368)
Cancer. 2008 Oct 1;113(7):1605-13. (PMID: 18683214)
Eur J Cancer. 2016 Jul;61:77-84. (PMID: 27155446)
Blood. 2022 Sep 15;140(11):1200-1228. (PMID: 35767897)
Cytometry A. 2013 Feb;83(2):179-81. (PMID: 23166007)
تواريخ الأحداث: Date Created: 20240517 Latest Revision: 20240518
رمز التحديث: 20240518
مُعرف محوري في PubMed: PMC11096644
DOI: 10.1002/hem3.64
PMID: 38756352
قاعدة البيانات: MEDLINE
الوصف
تدمد:2572-9241
DOI:10.1002/hem3.64